Umecrine Cognition

Executive Summary

Umecrine Cognition is a Swedish clinical-stage pharmaceutical company pioneering first-in-class small molecule therapies for neurological disorders driven by neuroinflammation. Its lead candidate, golexanolone, is a GABAA receptor-modulating steroid antagonist designed to reverse cognitive impairment and alertness deficits in conditions such as hepatic encephalopathy (HE) and Primary Biliary Cholangitis (PBC). By targeting the GABAergic system, which is dysregulated in neuroinflammatory states, golexanolone offers a novel mechanism distinct from current standard-of-care lactulose or rifaximin. The company has completed Phase 2a studies in HE and is advancing a Phase 2b trial to confirm efficacy. Additionally, a Phase 2 proof-of-concept study in PBC-related fatigue is underway, capturing an underserved patient population. With a strong intellectual property portfolio and clear differentiation from competitive assets, Umecrine Cognition is positioned to address significant unmet needs in hepatic and neurological indications. The company is privately held and actively seeking partnerships or non-dilutive funding to accelerate development, which could lead to a pivotal data readout within the next 12-18 months.

Upcoming Catalysts (preview)

• Q4 2026Phase 2b top-line data for golexanolone in hepatic encephalopathy55% success
• Q1 2027Phase 2 readout in Primary Biliary Cholangitis-related fatigue50% success
• Q2 2026New partnership or licensing deal for golexanolone in neurodegenerative indications40% success